This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients

This study has been completed.
Information provided by (Responsible Party):
Naoki Inui, Hamamatsu University Identifier:
First received: February 22, 2008
Last updated: September 5, 2011
Last verified: October 2009
A comparison of oral prednisolone administration with intravenous methylprednisolone infusion in the treatment of acute asthma exacerbation in hospitalized patients. Oral glucocorticosteroids administration may be effective as intravenous high-dose methylprednisolone infusion.

Condition Intervention Phase
Asthma Drug: methylprednisolone sodium succinate (mPSL) Drug: prednisolone (PSL) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 4, Randomized Study of Oral Glucocorticosteroid Administration in the Treatment of Acute Severe Asthma Exacerbation in Hospitalized Patients

Resource links provided by NLM:

Further study details as provided by Naoki Inui, Hamamatsu University:

Primary Outcome Measures:
  • Efficacy of oral prednisolone for the treatment of acute asthma [ Time Frame: three-year ]

Secondary Outcome Measures:
  • The safety of oral prednisolone for the treatment of acute asthma [ Time Frame: three-year ]

Enrollment: 50
Study Start Date: June 2007
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
mPSL 240 mg per day for 5 days
Drug: methylprednisolone sodium succinate (mPSL)
mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
Other Name: methlyprednisolone sodium succinate
Experimental: 2
PSL 40mg per day for 10 days
Drug: prednisolone (PSL)
PSL 40 mg per day for 10 days
Other Name: prednisolone


Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Asthma patients, who need hospitalized treatment, who do not respond with initial treatment including bronchodilator and IV methylprednisolone therapy

Exclusion Criteria:

  • Need for incubation
  • With severe complications
  • Received systemic glucocorticosteroid therapy in the previous 4 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00627731

Hamamatsu University School of Medicine
Hamamatsu, Japan
Sponsors and Collaborators
Hamamatsu University
Study Chair: Kingo Chida, MD,PhD Hamamatsu University
  More Information

Responsible Party: Naoki Inui, Department of Respiratory Medicine, Hamamatsu University Identifier: NCT00627731     History of Changes
Other Study ID Numbers: Hamamatsu-18-68
Study First Received: February 22, 2008
Last Updated: September 5, 2011

Keywords provided by Naoki Inui, Hamamatsu University:
Asthma Patients

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents processed this record on August 23, 2017